Revance Therapeutics, Inc. (NASDAQ:RVNC) CFO Sells $101,471.70 in Stock

Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Rating) CFO Tobin Schilke sold 3,201 shares of the firm’s stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $31.70, for a total value of $101,471.70. Following the transaction, the chief financial officer now owns 63,081 shares in the company, valued […]

Related Keywords

,Piper Sandler ,Tobin Schilke ,Nasdaq ,Jennison Associates ,Vanguard Group Inc ,Polar Capital Holdings Plc ,Allspring Global Investments Holdings ,Revance Therapeutics Company Profile ,Revance Therapeutics Inc ,Barclays ,Needham Company ,Securities Exchange Commission ,Revance Therapeutics ,Get Rating ,Exchange Commission ,Capital Holdings Plc ,Street Corp ,Global Investments Holdings ,Revance Therapeutics Daily ,Nasdaq Rvnc ,Rvnc ,Medical ,Insider Trading ,Nsider Trades ,Stocks ,